Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cue Biopharma
1UCCurrent price
1.43 EUR
+0.03 EUR (+2.14%)
Last closed
1.7 USD
Company
www.cuebiopharma.com
ISIN
US22978P1066
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
103 557 248 USD
Yield for 12 month
-36.97 %
1Y
3Y
5Y
10Y
15Y
1UC
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Address: 40 Guest Street, Boston, MA, United States, 02135
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4 USDP/E ratio
–Dividend Yield
–Current Year
+5 490 000 USD
Last Year
+1 245 227 USD
Current Quarter
+2 658 000 USD
Last Quarter
+1 717 000 USD
Current Year
+2 054 000 USD
Last Year
-560 828 USD
Current Quarter
+1 792 000 USD
Last Quarter
+868 000 USD
Key Figures 1UC
1 year
3 years
5 years
10 years
EBITDA
-47 706 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.11 %
PEG Ratio
–
Return On Equity TTM
-138.87 %
Wall Street Target Price
4 USD
Revenue TTM
8 295 000 USD
Book Value
0.45 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
92.3 %
Dividend Yield
–
Gross Profit TTM
1 245 227 USD
Earnings per share
-0.97 USD
Diluted Eps TTM
-0.97 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 1UC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1UC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 1UC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
10.222
Price Sales TTM
12.4843
Enterprise Value EBITDA
-1.7598
Price Book MRQ
4.7894
Financials 1UC
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 1UC
For 52 weeks
0.45 USD
3.25 USD
50 Day MA
1.05 USD
Shares Short Prior Month
3 800 384
200 Day MA
1.43 USD
Short Ratio
1.99
Shares Short
1 947 424
Short Percent
3.25 %
BeatStart